Wound care and regenerative medicine company Acelity registered for an initial public offering today that could raise as much as $1 billion, confirming rumors that 1st surfaced in June that its private equity owners are looking look to pay down debt.
Acelity, formerly Kinetic Concepts Inc., was acquired for $6.1 billion by Apax Partners and a pair of Canadian pension funds in a leveraged buyout in November 2011. The company, which makes wound care products, later folded KCI sister company LifeCell and acquisition Systagenix into the Acelity brand.
The San Antonio-based company reported sales growth of 7.7%, to $1.866 billion, for 2014 and pared its losses by 58.7%, to -$230.4 million, compared with 2013. For the 6 months ended June 30, sales grew 4.3% to $353.2 million, with losses cut 88.9% to $22.2 million, compared with the 1st half of 2014.
Today Acelity said it plans to trade on the New York Stock Exchange, but did not reveal a stock symbol. The company also said it plans to use the IPO proceeds to redeem some of the $609.6 million it has in 12.5% senior notes, which come due in 2019. Acelity had more than $1.73 billion in 10.5% 2nd-lien senior secured notes, due 2018, and total debt of $4.84 billion as of June 30.
In October 2013, then-KCI paid $485 million to acquire Systagenix, the wound care business spun out of Johnson & Johnson (NYSE:JNJ) in 2008. The company united Systagenix, LifeCell and KCI under the Acelity brand in September 2013.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.